+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure



Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure



International Journal of Cardiology 145(3): 438-443



Patients with chronic heart failure (HF) are characterized by alterations in matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) levels. However, the impact of hypolipidemic and antioxidant treatment in MMPs and TIMPs is unknown. In the present study, we sought to compare the effects of statins and xanthine oxidase inhibitors on circulating levels of MMPs and TIMPs in patients with chronic HF. Forty-two clinically stable patients with mild to moderate HF were randomized to receive rosuvastatin 10 mg or allopurinol 300 mg daily and followed up for 1 month. Serum levels of MMP-2, -9, TIMP-1, and -2 were measured before and after treatment. Levels of MMP-2 and -9 were significantly decreased in the rosuvastatin group (from 251±52 ng/ml and 400±206 ng/ml to 215±47 ng/ml and 309±166 ng/ml, p<0.001 and p<0.05 respectively), but not in the allopurinol group. In the rosuvastatin group, TIMP-2 levels were significantly increased (from 85±17 ng/ml to 93±16 ng/ml, p<0.05), while TIMP-1 remained unchanged. In the allopurinol group, no significant changes were observed regarding the levels of TIMPs. Short-term rosuvastatin but not allopurinol administration decreases MMP-2 and -9 and increases TIMP-2 levels.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052211914

Download citation: RISBibTeXText

PMID: 19539384

DOI: 10.1016/j.ijcard.2009.05.051


Related references

Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases levels in pediatric patients with congenital heart disease: Relationship to cardiac functions. Anadolu Kardiyoloji Dergisi 14(6): 531-541, 2014

Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thrombosis Research 115(3): 205-210, 2005

Circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with incisional hernia. Wound Repair and Regeneration 21(5): 661-666, 2014

Circulating levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases during Japanese encephalitis virus infection. Virusdisease 27(1): 63-76, 2016

Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes. International Journal of Cardiology 151(2): 237-239, 2011

Elevated levels of matrix metalloproteinases 2, 9 and tissue inhibitors of metalloproteinases -1, -4 in the vitreous humour of diabetic patients. IOVS 41(4): S652, 2000

Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease. Respirology 17(6): 1006-1012, 2012

Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis. Journal of the American Heart Association 2(2): E005868, 2013

Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. Clinical Biochemistry 41(18): 1466-1473, 2008

Clinical evaluation of serum levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases as predictors of progressive fibrosis in postoperative biliary atresia patients. Journal of Pediatric Surgery 37(7): 1030-1033, 2002

Human aqueous humor levels of transforming growth factor-β2: Association with matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases. Biomedical Reports 7(6): 573-578, 2017

Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia. Stroke 34(6): E37, 2003

Effect of simvastatin on serum matrix metalloproteinases-1, matrix metalloproteinases-9, tissue inhibitor of metalloproteinases-1, high sensitive C-reactive protein levels in patients of acute coronary syndrome in serum normocholesterolemia and hypercholesterolemia level. Zhonghua Xinxueguanbing Zazhi 32(2): 109-113, 2004

Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 113(17): 2089-2096, 2006

Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. Journal of Gastroenterology 42(2): 120-128, 2007